Cardiovascular Drugs Market Demands and
Growth Prediction, Outlook 2018-2026
Cardiovascular Drugs Market, by Drug Class (Anti-Hyperlipidemics, AntiHypertensive, Anti-Coagulants, Anti-Arrhythmic, Anti-Fibrinolytic, and Others
{Cardiac Glycosides, Anti-Ischemic Drugs, and Antianginal Drugs}), and by
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies) - Global Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026
Some of the common cardiovascular diseases include hypertensive heart disease, rheumatic heart
disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease. Major
problems associated with hypertensive heart disease include angina, hypertrophy, and heart failure.
These problems are caused due to high blood pressure in the heart’s arteries and muscles, which causes
narrowing of arteries and thickening and enlargement of heart.
Get The PDF Brochure of This Report :
https://www.coherentmarketinsights.com/insight/request-pdf/1167
The global cardiovascular drug market is primarily driven by increase in prevalence of heart diseases
coupled with rising geriatric population and lifestyle related diseases. In order to cater to this increasing
population suffering from cardiovascular diseases, drugs for treatment and prevention for these
diseases is required. Rising number of diabetic patients is also expected to be another factor for growth
of the global cardiovascular drugs market. According American Diabetes Association, in 2015, 30.3
Americans had diabetes, which is 9.4% of the total U.S population.
Manufacturers in the market are focusing on mergers and acquisition and new product launches, which
is positively affecting the market growth. However, stringent drug approval process and side effects of
some cardiovascular drugs hamper growth of the global cardiovascular drugs market. Moreover, the
patent expiry of various blockbuster drugs is also expected to adversely affect revenue growth of the
global cardiovascular drugs market.
Ask For Sample Copy of This Business Report @
https://www.coherentmarketinsights.com/insight/request-sample/1167
According to American Heart Association (AHA), in 2013, cardiovascular diseases accounted for over
17.3 million deaths globally, representing 31% of all global deaths. The global number is expected to
rise to 23.6 million by 2030. In 2010, the global burden of cardiovascular diseases was US$ 863
billion, and it is expected to rise to US$1044 billion by 2030. Around 2,200 U.S. citizens die due to
cardiovascular diseases, everyday, which is one death in every 40 seconds. Moreover, coronary heart
disease accounts for (45.1%) of the total cardiovascular disease, followed by stroke (16.5%), high
blood pressure (9.1%), heart failure (8.5%), diseases related to arteries (3.2%), and other cardiovascular
diseases in the U.S.
Some of the major players operating in the global cardiovascular drugs market are Pfizer Inc., Bayer
AG., Novartis AG., Merck and Co. Inc., AstraZeneca Plc, Bristol Myers Squibb Company, Abbott
Laboratories, Sun Pharma Industries, Gilead Sciences Inc., Otsuka Holdings Co., Ltd. Takeda
Pharmaceutical Company Ltd, Eli Lilly and Company, and Johnson & Johnson.
Increasing R&D activities to launch new products is expected to support in growth of the
cardiovascular drugs market
Regional segmentation of the cardiovascular drugs market by Coherent Market Insights comprises of
North America, Latin America, Europe, Asia Pacific, Africa, and Middle East. Global cardiovascular
drugs market is oligopolistic in nature with few players holding majority of the share. Various strategies
are adopted by key market players such as new product launches, and partnerships in order to retain
their market position.
For instance, in December 2017, Medicure Inc. — a Canada-based pharmaceutical company —
through its subsidiary Medicure International Inc., acquired exclusive license for 7 years to market and
sell cardiovascular drug for the treatment of primary hyperlipidemia or mixed dyslipidemia in the U.S
and its territories. In October 2017, the Sun Pharmaceutical Industries’ subsidiary in the U.S received
approval from the U.S Food and Drug Administration (FDA) to sell generic version of its Coreg CR.
Coreg CR is used to treat various heart conditions including high blood pressure and heart failure. In
August 2017, Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals entered into
partnership to develop next generation products for the treatment of cardiovascular diseases and heart
failure.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com
Some of the common cardiovascular diseases include hypertensive heart disease, rheumatic heart disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease.
© Copyright 2024 Paperzz
